Venous and arterial thrombo-embolic complications of hormonal treatment in a male-to-female transgender patient

2008 ◽  
Vol 15 (6) ◽  
pp. 714-716 ◽  
Author(s):  
G.M. Mullins ◽  
S.S. O’Sullivan ◽  
J. Kinsella ◽  
D. McEnroy ◽  
D. Crimmins ◽  
...  
2016 ◽  
Author(s):  
Blok Christel de ◽  
Maartje Klaver ◽  
Nienke Nota ◽  
Marieke Dekker ◽  
Heijer Martin den

2019 ◽  
Author(s):  
Paula Gonzalez-Diaz ◽  
Agnieszka Kuzior ◽  
Paula Maria Fernandez-Trujillo-Comenge ◽  
Manuel Esteban Nivelo Rivadeneira ◽  
Carmen Acosta-Calero ◽  
...  

1988 ◽  
Vol 152 (5) ◽  
pp. 638-640 ◽  
Author(s):  
P. L. E. Eklund ◽  
L. J. G. Gooren ◽  
P. D. Bezemer

On the basis of the records of subjects undergoing cross-gender hormonal treatment at the only gender treatment centre in the Netherlands, the prevalence of transsexualism was assessed over the years 1976–1986. In 1980, the prevalence was 1:45 000 for male-to-female and 1:200 000 for female-to-male transsexuals. In 1986 the prevalence for male-to-female transsexuals was 1:18 000, and for female-to-male transsexuals, 1:54 000. The increased prevalence is apparently due to a lower threshold for applying for medical treatment rather than to a true increase in the prevalence. Nevertheless, the calculated prevalence is higher than hitherto recorded. The ratio of male-to-female compared with female-to-male transsexuals was found to remain constant at 3:1.


2016 ◽  
Vol 23 (5) ◽  
pp. 391-397 ◽  
Author(s):  
Vinciane Corman ◽  
Iulia Potorac ◽  
Florence Manto ◽  
Sarah Dassy ◽  
Karin Segers ◽  
...  

Breast cancer is rare in male patients. Certain predisposing factors, be they genetic (e.g., BRCA2 gene mutations) or hormonal (imbalance between estrogen and androgen levels), have been implicated in male breast cancer pathophysiology. Male-to-female (MtF) transsexualism is a condition that generally involves cross-sex hormone therapy. Anti-androgens and estrogens are used to mimic the female hormonal environment and induce the cross-sex secondary characteristics. In certain situations, the change in the hormonal milieu can be disadvantageous and favor the development of hormone-dependent pathologies, such as cancer. We report a case of a MtF transgender patient who developed breast cancer after 7 years of cross-sex hormonal therapy. The patient was found to be BRCA2 positive, and suffered recurrent disease. The patient was unaware of being a member of an established BRCA2 mutation-positive kindred. This represents the first case of a BRCA2 mutation predisposing to breast cancer in a MtF transgender patient.


2009 ◽  
Vol 15 (3) ◽  
pp. 101-104
Author(s):  
Amos Adelowo ◽  
Emily E. Weber-LeBrun ◽  
Stephen B. Young

2010 ◽  
Vol 35 (8) ◽  
pp. 1213-1222 ◽  
Author(s):  
Beatriz Carrillo ◽  
Esther Gómez-Gil ◽  
Giuseppina Rametti ◽  
Carme Junque ◽  
Ángel Gomez ◽  
...  

2010 ◽  
Vol 21 (3) ◽  
pp. 278-282 ◽  
Author(s):  
Pansy Ferron ◽  
Sandra Young ◽  
Catherine Boulanger ◽  
Allan Rodriguez ◽  
Jose Moreno

2018 ◽  
Vol 30 (4) ◽  
pp. 661-663 ◽  
Author(s):  
Ankita Gupta ◽  
Sean Francis ◽  
Ryan Stewart ◽  
Deslyn Hobson ◽  
Kate V. Meriwether

Sign in / Sign up

Export Citation Format

Share Document